Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Eli Lilly and Company is conducting a Phase 3 clinical trial titled ‘A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)’. The study aims to assess the long-term effectiveness and safety of mirikizumab for treating ulcerative colitis, a chronic inflammatory bowel disease. This research is significant as it could offer a new long-term treatment option for patients with this challenging condition.
Intervention/Treatment: The intervention being tested is mirikizumab, administered subcutaneously. Mirikizumab is an experimental drug designed to treat moderately to severely active ulcerative colitis by targeting specific pathways involved in inflammation.
Study Design: This is an interventional study with a single-group assignment. There is no masking, meaning both researchers and participants know the treatment being administered. The primary purpose of the study is treatment-focused, aiming to evaluate the drug’s efficacy and safety over a long period.
Study Timeline: The study began on May 7, 2018, and is currently recruiting participants. The last update was submitted on August 22, 2025. These dates are crucial for tracking the study’s progress and ensuring transparency in its development.
Market Implications: The ongoing study of mirikizumab could significantly impact Eli Lilly’s stock performance, especially if results demonstrate strong efficacy and safety. Positive outcomes may boost investor confidence and position Eli Lilly favorably against competitors in the ulcerative colitis treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.